Procter Gamble Health Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Procter & Gamble Health Ltd is ₹ 5212 as of 18 May 11:57 . The P/E Ratio of Procter & Gamble Health Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Procter & Gamble Health Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Procter & Gamble Health Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Procter & Gamble Health Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Procter & Gamble Health Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Sanofi India Ltd changed from 119.34 % to 86.59 % over 5 quarters. This represents a CAGR of -22.63% .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Procter & Gamble Health Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Procter & Gamble Health Ltd or Sanofi India Ltd?

Market cap of Procter & Gamble Health Ltd is 8,775 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Procter & Gamble Health Ltd and Sanofi India Ltd?

The stock performance of Procter & Gamble Health Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Procter & Gamble Health Ltd and Sanofi India Ltd?

As of May 18, 2026, the Procter & Gamble Health Ltd stock price is INR ₹5286.55. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Procter & Gamble Health Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Procter & Gamble Health Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.